A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C

Göran B. Klintmalm, Gary L. Davis, Lewis Teperman, George J. Netto, Kenneth Washburn, Stephen M. Rudich, Elizabeth A. Pomfret, Hugo E. Vargas, Robert Brown, Devin Eckhoff, Timothy L. Pruett, John Roberts, David C. Mulligan, Michael R. Charlton, Thomas G. Heffron, John M. Ham, David D. Douglas, Linda Sher, Prabhakar K. Baliga, Milan Kinkhabwala & 5 others Baburao Koneru, Michael Abecassis, Michael Millis, Linda W. Jennings, Carlos G. Fasola

Research output: Contribution to journalArticle

Abstract

This randomized, prospective, multicenter trial compared the safety and efficacy of steroid-free immunosuppression (IS) to the safety and efficacy of 2 standard IS regimens in patients undergoing transplantation for hepatitis C virus (HCV) infection. The outcome measures were acute cellular rejection (ACR), severe HCV recurrence, and survival. The patients were randomized (1:1:2) to tacrolimus (TAC) and corticosteroids (arm 1; n = 77), mycophenolate mofetil (MMF), TAC, and corticosteroids (arm 2; n = 72), or MMF, TAC, and daclizumab induction with no corticosteroids (arm 3; n = 146). In all, 295 HCV RNA-positive subjects were enrolled. At 2 years, there were no differences in ACR, HCV recurrence (biochemical evidence), patient survival, or graft survival rates. The side effects of IS did not differ, although there was a trend toward less diabetes in the steroid-free group. Liver biopsy samples revealed no significant differences in the proportions of patients in arms 1, 2, and 3 with advanced HCV recurrence (ie, an inflammation grade ≥ 3 and/or a fibrosis stage ≥ 2) in years 1 (48.2%, 50.4%, and 43.0%, respectively) and 2 (69.5%, 75.9%, and 68.1%, respectively). Although we have found that steroid-free IS is safe and effective for liver transplant recipients with chronic HCV, steroid sparing has no clear advantage in comparison with traditional IS.

Original languageEnglish (US)
Pages (from-to)1394-1403
Number of pages10
JournalLiver Transplantation
Volume17
Issue number12
DOIs
StatePublished - Dec 2011

Fingerprint

Chronic Hepatitis C
Hepacivirus
Immunosuppression
Multicenter Studies
Steroids
Liver
Tacrolimus
Mycophenolic Acid
Adrenal Cortex Hormones
Recurrence
Safety
Survival
Graft Survival
Virus Diseases
Transplant Recipients
Fibrosis
Survival Rate
Transplantation
Outcome Assessment (Health Care)
RNA

ASJC Scopus subject areas

  • Surgery
  • Transplantation
  • Hepatology

Cite this

A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. / Klintmalm, Göran B.; Davis, Gary L.; Teperman, Lewis; Netto, George J.; Washburn, Kenneth; Rudich, Stephen M.; Pomfret, Elizabeth A.; Vargas, Hugo E.; Brown, Robert; Eckhoff, Devin; Pruett, Timothy L.; Roberts, John; Mulligan, David C.; Charlton, Michael R.; Heffron, Thomas G.; Ham, John M.; Douglas, David D.; Sher, Linda; Baliga, Prabhakar K.; Kinkhabwala, Milan; Koneru, Baburao; Abecassis, Michael; Millis, Michael; Jennings, Linda W.; Fasola, Carlos G.

In: Liver Transplantation, Vol. 17, No. 12, 12.2011, p. 1394-1403.

Research output: Contribution to journalArticle

Klintmalm, GB, Davis, GL, Teperman, L, Netto, GJ, Washburn, K, Rudich, SM, Pomfret, EA, Vargas, HE, Brown, R, Eckhoff, D, Pruett, TL, Roberts, J, Mulligan, DC, Charlton, MR, Heffron, TG, Ham, JM, Douglas, DD, Sher, L, Baliga, PK, Kinkhabwala, M, Koneru, B, Abecassis, M, Millis, M, Jennings, LW & Fasola, CG 2011, 'A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C', Liver Transplantation, vol. 17, no. 12, pp. 1394-1403. https://doi.org/10.1002/lt.22417
Klintmalm, Göran B. ; Davis, Gary L. ; Teperman, Lewis ; Netto, George J. ; Washburn, Kenneth ; Rudich, Stephen M. ; Pomfret, Elizabeth A. ; Vargas, Hugo E. ; Brown, Robert ; Eckhoff, Devin ; Pruett, Timothy L. ; Roberts, John ; Mulligan, David C. ; Charlton, Michael R. ; Heffron, Thomas G. ; Ham, John M. ; Douglas, David D. ; Sher, Linda ; Baliga, Prabhakar K. ; Kinkhabwala, Milan ; Koneru, Baburao ; Abecassis, Michael ; Millis, Michael ; Jennings, Linda W. ; Fasola, Carlos G. / A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. In: Liver Transplantation. 2011 ; Vol. 17, No. 12. pp. 1394-1403.
@article{4e8a12cd461842328552852b98e3c125,
title = "A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C",
abstract = "This randomized, prospective, multicenter trial compared the safety and efficacy of steroid-free immunosuppression (IS) to the safety and efficacy of 2 standard IS regimens in patients undergoing transplantation for hepatitis C virus (HCV) infection. The outcome measures were acute cellular rejection (ACR), severe HCV recurrence, and survival. The patients were randomized (1:1:2) to tacrolimus (TAC) and corticosteroids (arm 1; n = 77), mycophenolate mofetil (MMF), TAC, and corticosteroids (arm 2; n = 72), or MMF, TAC, and daclizumab induction with no corticosteroids (arm 3; n = 146). In all, 295 HCV RNA-positive subjects were enrolled. At 2 years, there were no differences in ACR, HCV recurrence (biochemical evidence), patient survival, or graft survival rates. The side effects of IS did not differ, although there was a trend toward less diabetes in the steroid-free group. Liver biopsy samples revealed no significant differences in the proportions of patients in arms 1, 2, and 3 with advanced HCV recurrence (ie, an inflammation grade ≥ 3 and/or a fibrosis stage ≥ 2) in years 1 (48.2{\%}, 50.4{\%}, and 43.0{\%}, respectively) and 2 (69.5{\%}, 75.9{\%}, and 68.1{\%}, respectively). Although we have found that steroid-free IS is safe and effective for liver transplant recipients with chronic HCV, steroid sparing has no clear advantage in comparison with traditional IS.",
author = "Klintmalm, {G{\"o}ran B.} and Davis, {Gary L.} and Lewis Teperman and Netto, {George J.} and Kenneth Washburn and Rudich, {Stephen M.} and Pomfret, {Elizabeth A.} and Vargas, {Hugo E.} and Robert Brown and Devin Eckhoff and Pruett, {Timothy L.} and John Roberts and Mulligan, {David C.} and Charlton, {Michael R.} and Heffron, {Thomas G.} and Ham, {John M.} and Douglas, {David D.} and Linda Sher and Baliga, {Prabhakar K.} and Milan Kinkhabwala and Baburao Koneru and Michael Abecassis and Michael Millis and Jennings, {Linda W.} and Fasola, {Carlos G.}",
year = "2011",
month = "12",
doi = "10.1002/lt.22417",
language = "English (US)",
volume = "17",
pages = "1394--1403",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "12",

}

TY - JOUR

T1 - A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C

AU - Klintmalm, Göran B.

AU - Davis, Gary L.

AU - Teperman, Lewis

AU - Netto, George J.

AU - Washburn, Kenneth

AU - Rudich, Stephen M.

AU - Pomfret, Elizabeth A.

AU - Vargas, Hugo E.

AU - Brown, Robert

AU - Eckhoff, Devin

AU - Pruett, Timothy L.

AU - Roberts, John

AU - Mulligan, David C.

AU - Charlton, Michael R.

AU - Heffron, Thomas G.

AU - Ham, John M.

AU - Douglas, David D.

AU - Sher, Linda

AU - Baliga, Prabhakar K.

AU - Kinkhabwala, Milan

AU - Koneru, Baburao

AU - Abecassis, Michael

AU - Millis, Michael

AU - Jennings, Linda W.

AU - Fasola, Carlos G.

PY - 2011/12

Y1 - 2011/12

N2 - This randomized, prospective, multicenter trial compared the safety and efficacy of steroid-free immunosuppression (IS) to the safety and efficacy of 2 standard IS regimens in patients undergoing transplantation for hepatitis C virus (HCV) infection. The outcome measures were acute cellular rejection (ACR), severe HCV recurrence, and survival. The patients were randomized (1:1:2) to tacrolimus (TAC) and corticosteroids (arm 1; n = 77), mycophenolate mofetil (MMF), TAC, and corticosteroids (arm 2; n = 72), or MMF, TAC, and daclizumab induction with no corticosteroids (arm 3; n = 146). In all, 295 HCV RNA-positive subjects were enrolled. At 2 years, there were no differences in ACR, HCV recurrence (biochemical evidence), patient survival, or graft survival rates. The side effects of IS did not differ, although there was a trend toward less diabetes in the steroid-free group. Liver biopsy samples revealed no significant differences in the proportions of patients in arms 1, 2, and 3 with advanced HCV recurrence (ie, an inflammation grade ≥ 3 and/or a fibrosis stage ≥ 2) in years 1 (48.2%, 50.4%, and 43.0%, respectively) and 2 (69.5%, 75.9%, and 68.1%, respectively). Although we have found that steroid-free IS is safe and effective for liver transplant recipients with chronic HCV, steroid sparing has no clear advantage in comparison with traditional IS.

AB - This randomized, prospective, multicenter trial compared the safety and efficacy of steroid-free immunosuppression (IS) to the safety and efficacy of 2 standard IS regimens in patients undergoing transplantation for hepatitis C virus (HCV) infection. The outcome measures were acute cellular rejection (ACR), severe HCV recurrence, and survival. The patients were randomized (1:1:2) to tacrolimus (TAC) and corticosteroids (arm 1; n = 77), mycophenolate mofetil (MMF), TAC, and corticosteroids (arm 2; n = 72), or MMF, TAC, and daclizumab induction with no corticosteroids (arm 3; n = 146). In all, 295 HCV RNA-positive subjects were enrolled. At 2 years, there were no differences in ACR, HCV recurrence (biochemical evidence), patient survival, or graft survival rates. The side effects of IS did not differ, although there was a trend toward less diabetes in the steroid-free group. Liver biopsy samples revealed no significant differences in the proportions of patients in arms 1, 2, and 3 with advanced HCV recurrence (ie, an inflammation grade ≥ 3 and/or a fibrosis stage ≥ 2) in years 1 (48.2%, 50.4%, and 43.0%, respectively) and 2 (69.5%, 75.9%, and 68.1%, respectively). Although we have found that steroid-free IS is safe and effective for liver transplant recipients with chronic HCV, steroid sparing has no clear advantage in comparison with traditional IS.

UR - http://www.scopus.com/inward/record.url?scp=82455192771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82455192771&partnerID=8YFLogxK

U2 - 10.1002/lt.22417

DO - 10.1002/lt.22417

M3 - Article

VL - 17

SP - 1394

EP - 1403

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 12

ER -